BioCryst Q1 Earnings Awaited After Landmark Year and Strategic Shifts

RESEARCH TRIANGLE PARK, N.C. – April 15, 2026 – BioCryst Pharmaceuticals has scheduled its first quarter 2026 financial report and conference call for May 6, an announcement that has investors and industry analysts keenly watching. While a routine disclosure, the upcoming report carries significant weight as it will provide the first concrete data points of the year following the company's transformative and first-ever profitable year in 2025. Stakeholders are eager for updates on the commercial trajectory of its flagship drug, ORLADEYO®, and the integration of its newly acquired assets in the competitive rare disease landscape.

The biotechnology firm, which focuses on treatments for hereditary angioedema (HAE) and other rare conditions, will host a webcast at 8:30 a.m. ET to dissect the financial results and offer a broader corporate update. This call will be a critical forum for management to frame the narrative for 2026, a year defined by strategic consolidation and aggressive pipeline expansion.

Riding the Wave of ORLADEYO's Success

The financial health of BioCryst is inextricably linked to the performance of ORLADEYO® (berotralstat), its oral, once-daily treatment for preventing attacks in patients with HAE. The drug was the primary engine behind the company’s stellar 2025 performance. Full-year net revenue for ORLADEYO surged to $601.8 million, a robust 38% increase year-over-year. When adjusted to exclude the now-divested European business, the revenue growth was an even more impressive 43% on a comparable basis, surpassing the company's own guidance.

This momentum was fueled by strong commercial execution, particularly in the United States. Throughout 2025, BioCryst reported high levels of new patient prescriptions, with the second quarter marking the highest number of new starts since the product's launch. This indicates not only sustained patient demand but also growing confidence among prescribers in a competitive market.

A significant milestone that will influence future growth was the U.S. Food and Drug Administration (FDA) approval in December 2025 for ORLADEYO oral pellets. This new formulation is for pediatric HAE patients aged 2 to less than 12 years, making it the first and only targeted oral prophylactic therapy for this vulnerable population. The launch and uptake of this pediatric version will be a key area of focus in the upcoming report, as it opens a new and previously unaddressed market segment.

Investors will be scrutinizing the Q1 2026 ORLADEYO sales figures to see if this powerful growth trend is continuing, especially as the company navigates an increasingly crowded HAE treatment space.

A Landmark Year and a Sharpened Focus

For BioCryst, 2025 was not just a year of strong sales; it was the year the company fundamentally altered its financial profile. For the first time in its history, the company achieved full-year GAAP profitability, reporting a net income of $263.86 million. This stands in stark contrast to the net loss of $88.88 million recorded in 2024 and signals a successful transition from a cash-burning development-stage biotech to a self-sustaining commercial entity.

This profitability was bolstered by a key strategic decision: the sale of its European ORLADEYO business. In October 2025, BioCryst completed the transaction with Neopharmed Gentili S.p.A., which generated $243.3 million in revenue. More importantly, the move streamlined the company's operating structure, allowing it to divest from a more complex international market and concentrate its resources on the high-value U.S. market. According to company guidance, the U.S. is expected to account for over 90% of ORLADEYO revenue in 2026, making this sharpened focus a cornerstone of its forward-looking strategy.

The upcoming financial report will provide the first glimpse into the company's performance under this new, more focused operational model.

Expanding the Arsenal: The Astria Acquisition and Pipeline

While solidifying its commercial foundation with ORLADEYO, BioCryst made an aggressive move to expand its future HAE franchise. In January 2026, the company completed its acquisition of Astria Therapeutics, a deal that significantly enhances its long-term pipeline. The centerpiece of this acquisition is navenibart, an injectable, long-acting monoclonal antibody inhibitor of plasma kallikrein designed for HAE prophylaxis.

Navenibart is currently in a Phase 3 clinical trial, ALPHA-ORBIT, and is positioned to compete directly with established injectable treatments in the HAE market. Promising Phase 2 data showed a 92% reduction in attack rates with no significant safety concerns. BioCryst is aiming for a regulatory filing by the end of 2027, and the acquisition diversifies its HAE portfolio beyond oral therapies, creating a multi-pronged approach to patient care.

The integration of the Astria team and the progress of the navenibart trial will be a major topic of interest during the May 6th call. The acquisition adds an estimated $70 million to $80 million in operating expenses for 2026 to support Phase 3 enrollment and manufacturing activities. Analysts will be looking for updates on trial enrollment velocity and management’s strategy for funding this expanded pipeline while maintaining profitability.

Beyond HAE, the company continues to advance other rare disease programs, including BCX17725 for Netherton syndrome, underscoring its broader commitment to addressing unmet medical needs.

Navigating a Competitive Landscape and Future Guidance

BioCryst does not operate in a vacuum. The HAE market is dynamic and features formidable competitors, including CSL Behring with its product Haegarda® and Takeda with its market-leading injectable Takhzyro®. The company itself acknowledged the launch of new prophylactic competitors in 2025, yet ORLADEYO continued to gain market share, a testament to the appeal of its oral, once-daily administration.

Looking ahead, BioCryst has issued confident guidance for 2026. It projects global net ORLADEYO revenue to be between $625 million and $645 million and expects to maintain non-GAAP profitability for the full year, even with the increased investment in the navenibart program. The May 6th report will be the first test of this guidance and will set the tone for the remainder of the year.

Ultimately, the investment community will be listening for confirmation that ORLADEYO’s growth engine is still running at full throttle, for clear updates on the integration and advancement of the promising navenibart program, and for management’s vision for sustaining its newfound profitability while navigating the complex and competitive currents of the rare disease market.